2020-2027 Analysis and Review Guaifenesin Market

Guaifenesin Market

Guaifenesin Market By Clinical Application (Chest Congestion and Asthma), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027

04-05-2020 REP-HC-5075 40 Tables 120 pages Format

The guaifenesin market was valued at USD 408.6 Mn by 2019. Significant increase in the number of patients suffering from chest congestion as a result of common cold, influenza, and other lower respiratory tract infection worldwide. Additionally, the availability of the over the counter (OTC) drug formulation containing guaifenesin in combination with other drugs will further accentuate the market growth.

 Guaifenesin Market

Guaifenesin is categorized as an expectorant that enhances the removal of phlegm and bronchial secretions by reducing the adhesiveness and viscosity of mucus, thereby facilitates the efficacy of mucociliary action in order to remove the mucus from the upper and lower respiratory tract.

The major segments related to the guaifenesin market are: 

By Clinical Application (2017–2027; US$ Mn)

Chest Congestion

Asthma

By Distribution Channel (2017–2027; US$ Mn)

Hospital Pharmacy

Retail Pharmacy

Others

Geography Segment (2017–2027; US$ Mn)

North America

United States
Canada

Europe

United Kingdom
Germany
Russia
France
Italy
Spain
Ukraine
Rest of Europe

Asia Pacific

China
Japan
Rest of Asia Pacific

Latin America (LATAM)

Brazil
Mexico
Rest of Latin America

Middle East and Africa (MEA)

GCC
Rest of MEA
 

Justification for study?

  • The intention of the study is to give a comprehensive outlook of the global guaifenesin market
  • The overall segmentation of the guaifenesin market, by clinical application, distribution channel, and geography is minutely studied. Chest congestion and hospital pharmacy are dominating the clinical application and distribution channel segments respectively
  • Constant rise in chest congestion in patients suffering from common cold and flu infection worldwide
  • Promising results achieved in the symptomatic relive in asthma patients receiving guaifenesin in combination therapy with ephedrine

Report gist?

The study of the global guaifenesin market includes qualitative analysis of factors such as drivers, restraints, and opportunities

The report covers qualitative and quantitative analysis of the overall market segmented on the basis of clinical application and distribution channel and categorization of the same at the geography level

This research report presents the analysis of each segment from 2017 to 2027 in which 2019 is considered as the base year. Compounded annual growth rate is calculated for the respective segments from 2020 to 2027

The study includes the profiles of major market players with a significant global and regional presence along with top company positioning. 

Significant customers?

  • This study is suitable for industry participants and stakeholders in the pharmaceutical companies actively engaged in the production and marketing of guaifenesin owing to the rising prevalence of chest congestion in patients suffering from common cold and flu infection
  • The report will benefit formulation scientist in manufacturing different combination of guaifenesin with other drugs to gain relief in chest congestion and asthma
  • Managers with financial institutions looking to publish recent and forecasted statistics pertaining to guaifenesin market
  • Financial institutions venture capitalist, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies 

Segment Analysis

Chest congestion is spearheading the clinical application segment for the guaifenesin market. The common causes associated with chest congestion are the common cold, influenza, asthma, bronchitis, allergic reactions, etc. Mucus is present in the body which secretes more as a consequence of lower respiratory tract infection which can lead to coughing and pain. Expectorants are beneficial in thinning the mucus and coughing it out of the lungs more easily. Asthma is expected to register rapid market growth on account of the frequent pain encountered in coughing during physical activity and shortness of breath. Guaifenesin is used in combination with ephedrine to provide symptomatic relief in patients suffering from asthma. 

Hospital pharmacy is currently dominating the distribution channel segment for the guaifenesin market. It is imperative to note that guaifenesin is associate with severe adverse events thus it becomes mandatory for the dispensing of guaifenesin by a hospital pharmacist the negate occurrence of any side effects. Retail pharmacy is gaining positive market growth in the developing regions on account of availability of combination drug formulation containing guaifenesin as a generic and over the counter product. 

North America is presently leading the geography segment for the guaifenesin market. The rising prevalence of common cold infection across all age groups primarily drives the market growth. According to the latest statistics presented by the Center for Disease Control and Prevention (CDC), annually there are approximately 75 million physicians visit pertaining to common cold infection in the United States, which is responsible for a healthcare burden of $ 7.7 billion per year. Additionally the presence of major players such as Pfizer, Inc., Reckitt Benckiser Group, plc, Aurohealth LLC, Strive Pharmaceuticals, Inc., etc further accentuate the market growth in the region. Europe is positioned in the 2nd place in the regional segment on account of the rising prevalence of seasonal influenza in the European Union region which peaks in the winter season. As per the recent research citings provided by the European Commission report influenza affects approximately 5% to 15% of the population in the region. Asia Pacific is anticipated to be the fastest-growing regional segment during the forecast period. Constant rise in the seasonal influenza infection due to the monsoon and subtropical climate in the region and flourishing generic drugs market.

Select License Type

$4,600
$6,600
$13,200

Safe and Secure SSL Encrypted

Have a Question?

We will help you find what you are looking for.

Call 1-518-730-1560

Contact sales

How can we help you?

Get in touch with us or find an office closest to you.